Back to results
US 2017/0360914 A1Published application
Universal cancer peptides derived from telomerase
AssigneesInvectys, Universite De Franche-Comte, Centre Hospitalier Regional Universitaire De Besancon
InventorsPierre Langlade Demoyen, Olivier Adotevi, Magalie Dosset
Life of this patent
Estimating the term…
Abstract
The invention relates to a peptide of 15 to 20 amino acids deriving from TERT protein, which peptide is capable of (i) binding to HLA class II and (ii) stimulating a CD4 Th response. These universal cancer peptides are especially useful in anti-tumor immunotherapy and immunomonitoring.
Claims7
1-15. (canceled)
A pharmaceutical composition comprising (i) a first peptide consisting of the sequence SLCYSILKAKNAGMS (SEQ ID NO:
- 3), (ii) a second peptide consisting of the sequence KSVWSKLQSIGIRQH (SEQ ID NO:
- 1), and (iii) a pharmaceutically acceptable excipient.
Dependencies are inferred from the claim text.